Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE)

Project Summary

PI(s): Jerry A. Krishnan, MD, PhD

PaTH Protocol PI(s): TBD

Purpose: Chronic obstructive pulmonary disease (COPD) affects 15 million Americans and leads to about 700,000 hospitalizations in the United States each year. Clinical trials suggest long-term use of roflumilast or azithromycin significantly reduces the risk of these exacerbations, but no studies have directly compared the two in patients with COPD.

Goal(s): To determine the side effects of roflumilast or azithromycin and see which treatment better prevents hospitalization.

Study Design: Pragmatic Randomized Clinical Trial. Adults with severe COPD related to chronic bronchitis who are current or past smokers and have been hospitalized for COPD exacerbation in the past 12 months will be randomly assigned roflumilast or azithromycin and followed up to 36 months.

PCORnet Partners: pending

PaTH Partners: pending

Sponsor: PCORI

Coordinating Center: University of Illinois at Chicago

How to Participate: This study has not yet started. Information will be provided when it is available.

PaTH Network Logo
Twitter Logo Facebook Logo LinkedIn Logo YouTube Logo

Copyright 2016 | PaTH Network